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1. Introduction 
Oxytocin (OT), a hormone exerting central and peripheral actions, plays an essential role in 
the mechanisms of parturition and lactation. It acts through its receptors, the number of 
which increases in the uterus towards labor, thus augmenting the uterotonic effect. 
Activated oxytocin receptors (OTR) by oxytocin, signal via a large number of intracellular 
pathways causing increased myometrial contractions by means of increased intracellular 
Ca+2 ion, increased myosin light chain phosphorylation and increased production of 
prostaglandins.  
Molecules that antagonize the action of oxytocin have been developed for use as tocolytic 
agents in the treatment of preterm labor. One presently available tocolytic, the oxytocin 
receptor antagonist atosiban, acts on both myometrial and decidual OTRs. However, 
research is in progress aimed at the development and clinical application of new oxytocin 
receptor antagonists with an enhanced pharmacological profile translating as higher affinity 
for the receptor as well as better bioavailability and improved safety. In this chapter we 
describe the function of oxytocin in labor and review the use of atosiban for the treatment of 
preterm labor, while also evaluating the current development of other OTR antagonists that 
are potential candidates as tocolytic drugs in the future. 
2. Oxytocin synthesis and function 
Oxytocin (OT) is a nine amino acid neuropeptide synthesized by the magnocellular neurons 
of the supraoptic and paraventricular nuclei of the hypothalamus. It is released into the 
circulation by exocytosis from the posterior pituitary and nerve terminals in response to 
various stimuli. The amino acids sequence in the OT molecule is:  Cysteine-Tyrosine-
Isoleukine-Glutamine-Asparagine-Cysteine-Proline-Leukine-Glycinamide, and with a sulfur 
bridge between the two cysteines. The structure of OT is very similar to that of the 
nonapeptide vasopressin, which differs from oxytocin by two amino acids. Oxytocin is also 
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synthesized in such peripheral tissues as the uterus, corpus luteum, placenta, amnion, and 
testis (Gimpl and Fahrenholz, 2001).  
Oxytocin, involved in numerous physiological and pathological processes, exerts a variety 
of actions, including the regulation of the hypothalamo-pituitary-adrenal axis in response to 
stress, cell proliferation, pregnancy, luteal function, maternal behavior, erectile function, and 
ejaculation (Viero et al., 2010).  
3. The oxytocin receptor signaling 
Oxytocin has only one receptor, which belongs to the rhodopsin-type class I G-protein 
coupled receptor (GPCR) superfamily.  The gene of the oxytocin receptor is present in a 
single copy on chromosome 3p25 and contains 3 introns and 4 exons. Oxytocin and other 
molecules of similar structure, such as arginine vasopressin (AVP) and oxytocin agonists or 
antagonists, can bind to the receptor. The affinity for OT is about 10-fold higher than for 
AVP. The cell surface transmembrane OTR is activated after binding of OT molecule, and 
the receptor subsequently causes activation of the various intracellular signal pathways, this 
finally resulting in the numerous effects of the hormone, including contraction. OTR is 
coupled to the Gq/11 a- class guanosine triphosphate (GTP) binding proteins. Binding of OT 
activates, via Gǂq/11, phospholipase C (PLC) which hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2) to inositol 1,4,5- triphosphate (InsP3) and diacylglycerol (DAG). InsP3 
results in the release of Ca2+ ions from intracellular stores, while DAG activates  protein 
kinases type C (PKC), which further phosphorylates other proteins, thus bringing about a 
trophic effect on myometrial cells via the eukaryotic translation elongation factor 2 (eEF2). 
Release of Ca2+ ions initiates smooth muscle contractions as Ca2+ binds to calmodulin and 
the Ca2+-calmodulin system activates myosin light-chain kinase. This mechanism causes 
myometrial contractions, as well as contraction of mammary myoepithelial cells leading to 
milk ejection (Gimpl and Fahrenholz, 2001). The major pathway that mediates the signal of 
OTR after binding of OT is the Gq/PLC/InsP3 pathway. The OTR is, however, also coupled 
with other G proteins, Gs and Gi, which give rise to various other cellular effects, e.g. 
inhibition of cellular growth (Viero et al., 2010).  
OTR additionally acts on voltage-gated or receptor coupled channels; this activation, which 
leads to membrane depolarization and the entry of extracellular Ca2+ into the cells, 
eventually triggers various cellular responses and further promotes smooth muscle 
contractility.  
OTR also activates the mitogen-activated protein kinase (MAPK) and the Rho kinase 
pathways. Rho associated protein kinases are involved in many cellular phenomena, among 
them cell migration, cell cycle control and cell contractility. Activation of OTR and MAPK 
results, in both cases, in elevated cytosolic phospholipase A2 (cPLA2) activity.  cPLA2 
hydrolyzes phospholipids while liberating arachidonic acid, that results in increased 
production of prostaglandins via cyclooxygenase-2 (COX-2),   an enzyme up-regulated by 
MAPK (Molnar and Hertelendy, 1995; Soloff et al., 2000). RhoA kinase increases 
phoshporylated myosin light chains. The increase in intracellular Ca2+ ions, the activation of 
the Rho and MAP kinase pathways, and the increased production and secretion of 
prostaglandins all together result in the contractile effects of OT-OTR activation.  
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4. Changes in circulating oxytocin and oxytocin receptor levels in labor 
In humans, circulating oxytocin is not necessary for the initiation and completion of 
parturition, since normal labor can be achieved in cases of pituitary dysfunction (Phelan et 
al., 1978). Additionally, oxytocin circulation levels do not increase significantly in pregnancy 
or at the beginning of labor but are increased at the expulsive stage, while oxytocin pulsatile 
changes occur in pregnant women at term.  Apart from in the pituitary, OT is also produced 
locally, and, in fact, placental OT acting in a paracrine fashion may be more important than 
circulating OT for the mechanism of labor.  OTR is also up-regulated at the end of gestation 
and sensitivity to oxytocin-induced contractions is greatly increased compared to the non-
pregnant uterus. A significant increase in the number of oxytocin receptors in the 
myometrium and decidua is observed in women with both term and preterm labor 
(Petraglia et al., 1996). Although steroid hormones are also thought to influence the number 
of OTR, the mechanisms of regulation are complex and not yet fully elucidated (Mirando et 
al., 1990, Wathes et al., 1996; Zingg et al., 1995). After parturition the binding sites of OT in 
uterus decline rapidly, while OTR expression in mammary glands remains high during the 
period of lactation (Petraglia et al., 2010).  
However, continuous exposure to high doses of oxytocin leads to desensitization and down-
regulation of OTR (Plested and Bernal, 2001). Desensitization is a phenomenon that prevents 
overstimulation of cells after prolonged agonist stimulation. This phenomenon is observed 
in GPCR receptors and is brought about by means of different mechanisms at many levels, 
such as phosphorylation, internalization or changes at the receptor mRNA levels. Rapid 
desensitization of GPCR receptors, taking place within seconds or minutes, occurs in two 
steps: 1. phosphorylation of the receptor, causing inhibition of G-protein activation; 2. 
binding of proteins, called arrestins, preventing G-protein activation and promoting 
receptor internalization.  Internalization of the receptor after continuous OT stimulation is 
yet another mechanism of desensitization. Though it has been suggested that once 
internalized, the receptor does not return to the cell surface, recent data suggest that 
intracellular trafficking and recycling of the OTR to the cell surface does indeed take place 
(Conti et al., 2009). OTR desensitization is a phenomenon that occurs after prolonged 
agonist stimulation, i.e. lasting for several hours (Terzidou, 2007). Continuous OT treatment 
reduces the mRNA of the OTR, this possibly due to suppression of OTR transcription or 
destabilization of the mRNA molecule.  In cultured human myometrial cells, treatment with 
OT for up to 20 hours causes OTR desensitization which effects in a reduction of the OT 
binding sites from 210 x 103 sites/cell to only 20.1 x 103 sites/cell, without receptor 
internalization. However, while the total amount of OTR protein is not diminished, 
treatment reduces OTR mRNA levels  (Phaneuf et al., 1998).   In vivo, in women with 
oxytocin-induced or oxytocin-augmented labor there is also a reduction in myometrial 
oxytocin binding sites and in OTR mRNA levels. Compared to women not in labor, in cases 
of oxytocin-augmented or oxytocin-induced labor, the median number of binding sites was 
reduced from to 477 fmol/mg-1 protein to 140 fmol/mg-1 protein and 118 fmol/mg-1 protein, 
respectively, both differences being statistically significant.  Compared to women not in 
labor, in cases of labor augmentation and induction OTR mRNA levels were reduced by 60- 
and 300-fold, respectively (Phaneuf et al., 2000). Oxytocin receptor down-regulation has 
great significance in clinical practice. Long-term oxytocin infusion may fail to augment labor 
or may lead to postpartum uterine atony which cannot be managed with additional 
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oxytocin infusion. However, oxytocin is normally secreted in pulses, this pulsatile secretion 
likely being a mechanism that prevents desensitization from occurring.  This might explain 
why in women in labor, induction of labor requires significantly lower doses of oxytocin 
when oxytocin is administered in pulses, compared with continuous oxytocin infusion 
(Dawood, 1995).  
5. Experimental or clinical use of oxytocin agonists 
The widespread distribution of OTR has led to the development of OTR agonist molecules 
that could be used as pharmacological tools (agents used experimentally to study the 
functions of oxytocin and its receptor) or as potential drugs for the management of obstetric 
disorders and neuropsychiatric diseases, including anxiety-related disorders, autism and 
schizophrenia. OTR agonists may be peptide (such as [Thr4]OT, [HO1][Thr4]OT, 
[Thr4,Gly7]OT and  [HO1][Thr4,Gly7]OT) or non-peptide molecules (such as WAY-267464 
and other compounds) (Borthwick, 2006; Manning et al., 2008). WAY-267464 exerts 
oxytocinergic actions, such as anxiolytic effects, in mice (Ring et al., 2010).  
Clinically, synthetic oxytocin is used for labor induction and augmentation and the 
treatment of postpartum hemorrhage. Carbetocin, a synthetic oxytocin analog, is also 
indicated for prevention of uterine atony after delivery by cesarean section in spinal or 
epidural anesthesia. It also has the advantage of longer half life than oxytocin (4-10 times) 
and it is administered in a single dose, intramuscularly or intravenously, compared to 
oxytocin continuous infusion (Rath, 2009).  
6. Tocolytic action of oxytocin antagonists  
Since the most recognized signs of preterm labor are uterine contractions, the main 
method for postponement of preterm labor is currently the pharmacological inhibition of 
uterine contractions.  The inhibition of myometrial contractions is called tocolysis, and a 
drug administered to that end is referred to as a tocolytic agent. The aim of tocolytic 
agents is to maintain pregnancy for 24-48 hours, to allow the beneficial effects of 
corticosteroids administration to take place (reduced risk of perinatal death, neonatal 
respiratory distress syndrome, etc), usually after 18 hours, and also to permit safe transfer 
of the mother to a center with neonatal intensive care facilities. There are several  
tocolytics agents, such as ritodrine (a beta-receptor agonist), calcium-channel blockers, 
nitric oxide donors (as glyceryl trinitrate), and COX-2 inhibitors such as indomethacin 
(Simhan and Caritis, 2007).  
Selective human oxytocin receptor antagonists, such as atosiban and barusiban have also 
been synthesized as tocolytic agents for the management of preterm labor. Atosiban, an 
oxytocin analog (1-Deamino-2-D-Tyr-(O-ethyl)-4-Thr-8-ornoxytocin), is based on 
modification of amino acids in the structure of oxytocin at positions 1, 2, 4 and 8, thus being 
a competitive inhibitor of the OTR that blocks OT binding. It is also a mixed vasopressin 
V1a/OT antagonist that results in the incidence of related unwanted effects. Vasopressin 
V1a receptors (V1aR) expression are also present in myometrium.   
The onset of uterine relaxation after atosiban administration is fast. Atosiban is given 
intravenously as shown in Table 1 and the total dose should preferably not exceed 330 mg. 
www.intechopen.com
 
Oxytocin and Myometrial Contractility in Labor 
 
247 
Dose and administration 
Step 1 6.75 mg i.v. bolus, in one minute 
Step 2 18 mg/h i.v. i.v. infusion for 3 hours 
Step 3 6 mg/h i.v. i.v. infusion for up to 45 hours 
Side effects: Nausea, vomiting, hyperglycemia, headaches, dizziness, tachycardia, hot flushes, 
hypotension, injection site reactions, pruritis, rush, pyrexia, insomnia 
Table 1. Dose, method of administration, and side effects of atosiban.  
Clinically, atosiban, which requires continuous intravenous administration, is as effective as 
ǃ2-adrenergic agonists, but without producing their adverse effects.  Subcutaneously 
administered after a period of preterm labor, atosiban given as maintenance therapy was 
not shown to be associated with a reduction of the incidence of preterm birth nor with any 
improvement of neonatal outcome. In a study in which a total of 513 women were 
randomized to receive either atosiban or placebo administered with a subcutaneous infusion 
pump in order to prevent recurrence of preterm birth, atosiban compared to placebo did not 
reduce the incidence of preterm birth before 37 weeks (RR 0.89; 95% CI 0.71 to 1.12), 32 
weeks (RR 0.85; 95% CI 0.47 to 1.55), or 28 weeks (RR 0.75; 95% CI 0.28 to 2.01).  Outcomes 
were also similar for both groups with respect to birth weight, respiratory distress 
syndrome, patent ductus arteriosus, necrotizing enterocolitis, and intraventricular 
hemorrhage (Papatsonis et al., 2009).  
In Europe and other countries atosiban is the only oxytocin/vasopressin antagonist used 
today for preterm delivery.  However, this does not apply to the USA where the Food and 
Drug Administration has not granted approval of the drug as a tocolytic because of 
sufficient lack of evidence as to its efficacy and improvement of neonatal outcomes. 
Clinical studies have determined that atosiban is safer than beta-receptor agonists. A large 
study (Worldwide Atosiban versus Beta-agonists Study Group, 2001) demonstrated that 
atosiban was comparable in clinical effectiveness to conventional beta-agonist therapy 
(ritodrine, salbutamol or terbutaline), but was better tolerated and was associated with fewer 
maternal cardiovascular side effects (ClinicalTrials.gov, 2001).  Atosiban is also safer than 
calcium channel blockers. Meanwhile, clinical studies have shown nifedipine to be equally 
effective as atosiban, although the maternal side effects were significantly more common among 
women allocated to nifedipine rather than atosiban (Al-Omari et al., 2006). Cyclooxygenase 
inhibitors act as tocolytics by inhibiting prostaglandins production but also present significant 
side effects (King et al., 2005). Conversely, evidence is as yet not strong enough for 
recommendation of the use of nitric oxide donors as inhibitors of preterm delivery (Duckitt and 
Thornton, 2002). Nevertheless, atosiban  has not been proven to be superior in terms of neonatal 
outcome, concerns having been expressed in other studies (Papatsonis et al., 2005). 
Atosiban’s limited bioavailability—which necessitates parenteral administration and 
hospitalization—together with its low affinity for OTR and the binding to V1a receptors that 
causes side effects, have led to endeavors for the identification of new peptide and non-
peptide oxytocin antagonists for the management of preterm labor. While many such 
substances have been discovered, these drugs are still being evaluated at the experimental 
level and clinical studies in most cases have ceased or have been completed unsuccessfully 
(Manning et al., 2008). These compounds are either peptide or non-peptide molecules.  
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The OT antagonists shown in Table 2 bind for both oxytocin and AVP receptors.  However, 
limitations exist, these being: a) there are major differences among them with regard to their 
selectivity for a specific OT receptor; b) selectivity also varies according to the AVP receptor 
(V1a, V1b, V2); c) there are striking differences among species as to both receptors’ affinity 
for a given antagonist; and d) specification as to receptors’ affinity varies in the literature 
according to the experimental method used.  
 
 Oxytocin antagonists 
OT and AVP receptor 
binding 
I. Peptide 
Atosiban Yes 
FE 200 400 (Barusiban) Yes 
II. Non-peptide 
GSK221149A (Retosiban) Yes 
SSR-126768A Yes 
L-368,899 Yes 
Table 2. OT antagonists with tocolytic action and AVP receptor binding  
The V2 and V1a peptide antagonist d(CH2)5[Tyr(Me)2]AVP (known as Manning compound) 
is a potent OT antagonist in vitro and in vivo (Chan et al., 1996).  d(CH2)5[Tyr(Me)2]AVP is 
also a mixed V1a/OT antagonist for human VP and OT receptors.  
Several others highly selective OT peptidic antagonists have been designed and synthesized.  
These include d(CH2)5[Tyr(Me)2]OVT, desGly–NH2,d(CH2)5[Tyr(Me)2,Thr4]OVT  (which is 
about 18 times more potent as an OT antagonist in the rat than as a V1a antagonist) and 
desGly–NH2,d(CH2)5[D-Tyr2,Thr4]OVT (which is 95 times more potent as an OT antagonist 
in the rat than as a V1a antagonist). Moreover, the peptide d(CH2)5,[D-Thi2,Thr4,Tyr–NH29 
]OVT is a very selective oxytocin antagonist while being a very weak V1a antagonist, as is 
also desGly–NH2,d(CH2)5 [D-Trp2, Thr4, Dap5]OVT in the rat.  On the other hand, there are 
between species striking differences in the affinity of most antagonists for OT and AVP 
receptors. The first peptide above, d(CH2)5[Tyr(Me)2]OVT, is 5 times more potent as an V1a 
antagonist than as a OT antagonist in the rat,  whereas in humans it is about 9 times more 
potent as an OT antagonist than as a V1a antagonist.  
Some of the new peptide OT/VP antagonists have higher affinity for human receptor than 
the peptide atosiban, which, as noted, is the only antagonist used today in Europe. These 
new peptides are  desGly–NH2,d(CH2)5[D-2-Nal2,Thr4]OVT, desGly–NH2,d(CH2)5[2-
Nal2,Thr4]OVT, d(CH2)5[D-2-Nal2,Thr4,Tyr–NH29 ]OVT, and d(CH2)5[2-Nal2, Thr4, Tyr–NH29 
]OVT. These four peptides may be candidates as potential tocolytic agents for the 
prevention of preterm labor (Manning et al., 2008). 
Barusiban is a selective peptide oxytocin antagonist that exerts a high affinity for the human 
oxytocin receptor On the contrary, it displays low affinity for the vasopressin (V1a) receptor.  
It possesses greater potency and a longer duration of action than atosiban.  Contractility 
studies with isolated human myometrium have revealed that barusiban inhibits oxytocin-
induced myometrial contractions of both preterm and term myometrium, this action being 
at least as potent as that of atosiban (Pierzynski et al., 2004). In a study with eight pregnant 
monkeys, following induction of stable contractions by OT, barusiban or atosiban were 
administered. Barusiban’s duration of action was generally longer than 13–15 hours, while 
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atosiban's effect ceased within 1.5–3 hours. For long-term treatment, continuous high-dose 
infusions of barusiban (150 μg/kg/h) or the beta-2 agonist fenoterol (3 μg/kg/h) were 
administered. Barusiban reduced uterine activity in response to daily OT challenge and 
prolonged pregnancy more effectively than fenoterol (Reinheimer, 2007).   
Although barusiban suppresses oxytocin-induced preterm labor in non-human primates, in 
a recent study it was no more effective than placebo in terminating preterm labor in 
pregnant women at between 34+0-35+6 weeks of gestation. This study was conducted at 21 
participating centers with subjects from six different European countries.  Participants were 
randomly assigned to receive a single intravenous bolus dose of 0.3, 1, 3, or 10 mg barusiban 
or placebo (acetate buffer). The percentage of women who did not deliver within 48 hours 
was not significantly different between the placebo group and any of the barusiban groups 
(P = 0.21-0.84). No significant decreases in the number of uterine contractions compared 
with placebo were registered. All doses of barusiban were well tolerated and there were no 
adverse events that would lead to withdrawal from the study. Finally, there was no 
statistically significant difference in maternal or neonatal adverse effect between the placebo 
and barusiban groups (Thornton et al., 2009). 
The lack of peptide antagonists characterized by oral bioavailability have led researchers to 
seek an effective non-peptide oxytocin antagonist. The non-peptide oxytocin antagonist 2’-
methyl-1’,3’-oxazol-4’-yl morpholine amide derivative 74 (GSK221149A or retosiban) when 
administered orally or intravenously produced a dose-dependent decrease in oxytocin-
induced uterine contractions in rats, after either single or multiple dosing for 4 days. In 
addition, spontaneous uterine contractions in late-term pregnant rats (at 19–21 days gestation) 
were significantly reduced by intravenous administration of GSK221149A at a dose of 0.3 
mg/kg. In vitro experiments using Chinese hamster ovary (CHO) cell membranes expressing 
human OT receptors or human V1a, V1b, or V2 receptors, and human endothelial kidney 
(HEK) cells expressing rat oxytocin receptors showed that GSK221149A also has a higher 
affinity for human and rat oxytocin receptors than for V1a and V2 receptors (McCafferty et al., 
2007). GSK221149A is over 15-fold more potent compared to atosiban for the OTR (Borthwick 
and Liddle, 2011). GSK221149A is on a Phase ll Clinical trial described as “A randomized, 
double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, 
pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and to 
investigate the pharmacokinetics of GSK221149A administered orally to healthy, pregnant 
females with uncomplicated pre-term labor between 30+0 and 356 weeks' gestation” . The 
estimated date for study completion was June 2011 and no results have so far been published.   
Another non-peptide molecule, 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl) 
butyramido) bicyclo[2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4(2methylphenyl) piperazine, 
known as L-368,899, was shown to be a potent OT antagonist that inhibits spontaneous 
nocturnal uterine contractions in pregnant rhesus monkeys. L-368,899 also blocked OT-
stimulated uterine activity in postpartum women with a potency similar to that in the 
pregnant rhesus monkey (Pettibone et al., 1995). The pharmacokinetics and oral 
bioavailability, however, were suboptimal, and further clinical evaluation was not 
undertaken (Freidinger and Pettibone, 1997). L-368,899 is moreover brain penetrant. In a 
study, the non-peptide OT antagonist L-368,899 was accumulated when injected 
intravenously in four male monkeys in limbic brain areas. This antagonist when injected iv 
in one adult female monkey altered maternal and sexual behavior (Boccia et al., 2007). 
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WAY-162720 is another high-affinity, potent, and selective non-peptide antagonist of the 
OTR. WAY-162720 also penetrates the brain and is a tool for studies of OT on the CNS 
effects. In one study, the effects of OT on both the behavioral and autonomic parameters of 
the anxiety response in male mice were examined. Oxytocin showed an anxiolytic-like effect 
comparable to those observed with the reference anxiolytic alprazolam. The administration 
of WAY-162720 fully reversed the effects of centrally administered OT (Ring et al., 2006). 
The non-peptide SSR-126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl) -3-
methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, 
hydrochloride) produced a competitive antagonistic effect against OT in rat myometrial 
strips, while after oral administration in conscious pregnant rats in labor it significantly 
delayed parturition, in a manner similar to ritodrine. The onset of its action was rapid and 
the duration was still observed 24h after treatment. In experiments performed in human 
uterine sections in term pregnancies,  SSR-126768A inhibited the response to OT and this 
effect was observed in a concentration-dependent manner (Serradeil-Le et al., 2004).  
Relcovaptan, a vasopressin (V1a) receptor antagonist, was  reported to inhibit uterine 
contractions in women with preterm labor, thus indicating a role for V1a receptors 
(Steinwall et al., 2005). In a study including 18 women with preterm labor between 32–36 
weeks, 12 patients received at random a single oral dose of 400 mg relcovaptan and 6 
patients received placebo; uterine contractions were monitored up to 6h after 
administration. Relcovaptan inhibited uterine contractions and the decrease in the frequency 
of contractions was significantly higher than the frequency in the placebo-treated group. It 
has also shown positive initial results when used against Raynaud's disease and 
dysmenorrhea,  although it has not yet been approved for clinical use (Decaux et al., 2008). 
When relcovaptan was given orally once a day for 7 days in patients with Raynaud's 
disease, it showed favorable effects compared with placebo on finger systolic pressure and 
temperature recovery after cold immersion, without inducing side effects (Hayoz et al., 
2000). Relcovaptan is administered orally 100 mg or 300 mg daily in women suffering from 
primary dysmenorrhoea, from 4 hours up to a maximum of 3 days before the onset of 
bleeding and/or menstrual pain. After the start of dysmenorrhea (defined as the onset of 
vaginal bleeding or the onset of pain, whichever occurred first), treatment was prolonged 
for up to 3 days. Relcovaptan showed a therapeutic effect in the prevention of 
dysmenorrhea (Brouard et al., 2000). Relcovaptan also produced significant neuroprotective 
actions and reduced ischemic brain edema in an embolic model of stroke in rats when given 
immediately or 1 hour after middle cerebral artery occlusion, but not when administered at 
3 hours after middle cerebral artery occlusion (Shuaib et al., 2002). 
As our knowledge on OT/OTR system expands, the development and use of different OTR 
antagonists becomes an increasingly promising field in the management of preterm labor. 
7. Conclusion 
OT exerts its myometrial and other actions through a transmembrane receptor that belongs 
to the G- protein coupled receptor superfamily. Various peptide and non-peptide 
antagonists have been developed in order to be used as potential tocolytic agents or as 
research tools in assessing different OT functions. Atosiban is at present the only available 
OTR antagonist used as a tocolytic agent. Barusiban, L-368,899, SSR-126768A, and 
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GSK221149A (retosiban) are some other OTR antagonists demonstrating tocolytic properties 
when tested, but have not so far been approved for clinical use.  
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